CA2964162C - Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl - Google Patents

Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl Download PDF

Info

Publication number
CA2964162C
CA2964162C CA2964162A CA2964162A CA2964162C CA 2964162 C CA2964162 C CA 2964162C CA 2964162 A CA2964162 A CA 2964162A CA 2964162 A CA2964162 A CA 2964162A CA 2964162 C CA2964162 C CA 2964162C
Authority
CA
Canada
Prior art keywords
methoxy
amino
compound
methoxyphenyl
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2964162A
Other languages
English (en)
Other versions
CA2964162A1 (fr
Inventor
Becker Hewes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2964162(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2964162A1 publication Critical patent/CA2964162A1/fr
Application granted granted Critical
Publication of CA2964162C publication Critical patent/CA2964162C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés 4-anilino-3-quinoléinecarbonitriles utiles pour le traitement d'un sujet souffrant d'une leucémie BcrAbl positive résistante à l'imatinib. De telles leucémies comprennent celles qui ont, dans les cas de résistance, une mutation d'un aminoacide dans la protéine BcrAbl, par exemple F359V, H396P, I432T, F486S, M244V, L248V, G250E, Y253H, Y253F, E255K, K263E, L273M, T315I, F317L et N331S.
CA2964162A 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl Active CA2964162C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01
CA2868899A CA2868899C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2868899A Division CA2868899C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl

Publications (2)

Publication Number Publication Date
CA2964162A1 CA2964162A1 (fr) 2008-12-11
CA2964162C true CA2964162C (fr) 2019-12-31

Family

ID=39639071

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2688467A Active CA2688467C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoleine-3-carbonitriles
CA2868899A Active CA2868899C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl
CA2964162A Active CA2964162C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2688467A Active CA2688467C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoleine-3-carbonitriles
CA2868899A Active CA2868899C (fr) 2007-06-01 2008-05-30 Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles ayant une mutation dans le gene bcr-abl

Country Status (23)

Country Link
US (1) US11103497B2 (fr)
EP (4) EP2777704A3 (fr)
JP (3) JP5888853B2 (fr)
KR (1) KR101493543B1 (fr)
CN (1) CN101686973B (fr)
AU (1) AU2008260070B9 (fr)
BR (1) BRPI0812355A2 (fr)
CA (3) CA2688467C (fr)
CL (1) CL2008001577A1 (fr)
CY (2) CY1115251T1 (fr)
DK (2) DK2478905T3 (fr)
ES (2) ES2881391T3 (fr)
HU (1) HUE055524T2 (fr)
IL (1) IL202407A0 (fr)
MX (1) MX2009013069A (fr)
PA (1) PA8782301A1 (fr)
PL (2) PL3002009T3 (fr)
PT (2) PT3002009T (fr)
RU (1) RU2464026C2 (fr)
SI (2) SI3002009T1 (fr)
TW (1) TW200908982A (fr)
WO (1) WO2008150957A2 (fr)
ZA (1) ZA200908480B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777704A3 (fr) * 2007-06-01 2015-01-21 Wyeth LLC Traitement de leucémie résistant à l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
EP4746884A2 (fr) * 2023-07-21 2026-05-27 Icahn School of Medicine at Mount Sinai Inhibiteurs de la g9a/glp et méthodes d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2434526C (fr) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Procedes relatifs a l'administration d'analogues de l'epothilone pour le traitement du cancer
EP2341133A1 (fr) 2001-10-05 2011-07-06 Novartis AG Mutants de domaines de la kinase de l'ABL
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
CA2543163A1 (fr) 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles destines au traitement de la leucemie myeloide chronique (lmc)
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
AU2006270187A1 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
WO2007056177A2 (fr) * 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company Mutations t315a et f317i de domaine kinase de bcr-abl
EP2777704A3 (fr) * 2007-06-01 2015-01-21 Wyeth LLC Traitement de leucémie résistant à l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles

Also Published As

Publication number Publication date
EP2478905A2 (fr) 2012-07-25
HUE055524T2 (hu) 2021-11-29
RU2009144128A (ru) 2011-07-20
CY1124391T1 (el) 2022-07-22
EP3002009B1 (fr) 2021-07-07
CN101686973A (zh) 2010-03-31
JP2014111629A (ja) 2014-06-19
RU2464026C2 (ru) 2012-10-20
CA2964162A1 (fr) 2008-12-11
EP3002009A3 (fr) 2016-07-06
AU2008260070B2 (en) 2011-08-18
DK2478905T3 (da) 2014-06-30
IL202407A0 (en) 2010-06-30
EP2777704A2 (fr) 2014-09-17
PT3002009T (pt) 2021-08-02
AU2008260070A1 (en) 2008-12-11
EP2478905A3 (fr) 2013-01-16
HK1142812A1 (en) 2010-12-17
CN101686973B (zh) 2013-06-19
PA8782301A1 (es) 2009-01-23
WO2008150957A3 (fr) 2009-08-06
US11103497B2 (en) 2021-08-31
ZA200908480B (en) 2010-08-25
AU2008260070B9 (en) 2012-01-19
US20080318971A1 (en) 2008-12-25
JP5888853B2 (ja) 2016-03-22
TW200908982A (en) 2009-03-01
PL2478905T3 (pl) 2014-10-31
WO2008150957A2 (fr) 2008-12-11
BRPI0812355A2 (pt) 2015-01-27
CY1115251T1 (el) 2017-01-04
EP2777704A3 (fr) 2015-01-21
SI2478905T1 (sl) 2014-07-31
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CA2688467C (fr) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2152267A2 (fr) 2010-02-17
KR101493543B1 (ko) 2015-02-13
JP2016074700A (ja) 2016-05-12
CL2008001577A1 (es) 2008-07-25
PL3002009T3 (pl) 2021-12-13
EP2478905B1 (fr) 2014-05-14
CA2868899A1 (fr) 2008-12-11
EP3002009A2 (fr) 2016-04-06
CA2868899C (fr) 2017-06-13
SI3002009T1 (sl) 2021-09-30
PT2478905E (pt) 2014-07-16
KR20100017983A (ko) 2010-02-16
CA2688467A1 (fr) 2008-12-11
MX2009013069A (es) 2010-03-17
ES2477567T3 (es) 2014-07-17

Similar Documents

Publication Publication Date Title
CA2688467C (fr) Traitement de leucemie resistant a l'imatinib en utilisant des 4-aminoquinoleine-3-carbonitriles
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
US20040266834A1 (en) Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US9457016B2 (en) Methods for treating polycystic kidney disease
HK1142812B (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
WO2006024494A1 (fr) Utilisation de midostaurine pour le traitement de tumeurs du stroma gastro-intestinal
WO2005047259A1 (fr) 4-anilino-3-quinolinecarbonitriles destines au traitement de leucemie myelogene chronique (cml)
WO2026086864A1 (fr) Utilisation combinée d'un inhibiteur de kat6
US20080119463A1 (en) 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (fr) 4-anilino-3-quinolinecarbonitriles utilisables pour le traitement de la leucémie aigue myéloblastique (lam)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170412

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260413

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260413